{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:00:17Z","timestamp":1780664417497,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.acvd.2025.12.010","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:07:10Z","timestamp":1769713630000},"page":"461-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tafamidis treatment in transthyretin cardiac amyloidosis: A retrospective cohort analysis of outcomes and associated factors"],"prefix":"10.1016","volume":"119","author":[{"given":"Johanna","family":"Krief","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Aguilhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Delbaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Agullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Dupasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"H\u00e9don","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Femenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawel","family":"Aouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Pasquie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Pissarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Moulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roubille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2025.12.010_bib0220","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0225","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2025.12.010_bib0230","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0235","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.12.010_bib0240","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.12.010_bib0245","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.12.010_bib0250","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.acvd.2024.04.007","article-title":"Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: findings from the CAMPOS-TAVI study","volume":"117","author":"Costa","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.12.010_bib0260","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0265","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.12.010_bib0270","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0275","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob Heart"},{"key":"10.1016\/j.acvd.2025.12.010_bib0280","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.12.010_bib0285","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection\u00a0\u2013\u00a0a review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom J"},{"key":"10.1016\/j.acvd.2025.12.010_bib0290","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.acvd.2024.08.006","article-title":"Clinical outcomes for 2788 patients with transthyretin amyloidosis: tafamidis meglumine early access program in France","volume":"118","author":"Lairez","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.12.010_bib0295","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0300","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40256-021-00464-y","article-title":"Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with tafamidis","volume":"21","author":"Vong","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.acvd.2025.12.010_bib0305","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pcad.2018.05.005","article-title":"Obesity and the obesity paradox in heart failure","volume":"61","author":"Horwich","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.12.010_bib0310","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCHEARTFAILURE.111.962290","article-title":"Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims","volume":"4","author":"Kociol","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0315","first-page":"424","article-title":"Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems","volume":"36","author":"Cappelli","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0320","doi-asserted-by":"crossref","first-page":"132469","DOI":"10.1016\/j.ijcard.2024.132469","article-title":"Value of troponin and NT-proBNP to screen for cardiac amyloidosis after carpal tunnel syndrome surgery","volume":"415","author":"Noory","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0325","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1002\/ehf2.12989","article-title":"Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage","volume":"7","author":"Law","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0330","doi-asserted-by":"crossref","first-page":"e036755","DOI":"10.1161\/JAHA.124.036755","article-title":"Predictors of early death in patients with wild-type transthyretin cardiac amyloidosis","volume":"14","author":"Milani","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2025.12.010_bib0335","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ejhf.3354","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0340","series-title":"Avis et r\u00e9f\u00e9rentiel\u00a0: t\u00e9l\u00e9surveillance m\u00e9dicale du patient insuffisant cardiaque chronique [Opinion and guidelines: medical telemonitoring of the chronic heart failure patient]","year":"2022"},{"key":"10.1016\/j.acvd.2025.12.010_bib0345","doi-asserted-by":"crossref","first-page":"1151803","DOI":"10.3389\/fcvm.2023.1151803","article-title":"Risk stratification in transthyretin-related cardiac amyloidosis","volume":"10","author":"Scirpa","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.acvd.2025.12.010_bib0350","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0355","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0360","doi-asserted-by":"crossref","first-page":"101571","DOI":"10.1016\/j.cpcardiol.2022.101571","article-title":"Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis","volume":"48","author":"Bukhari","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0365","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/ehf2.13851","article-title":"Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis","volume":"9","author":"Papathanasiou","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0370","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.echo.2022.10.010","article-title":"Multichamber strain predicts atrial fibrillation in cardiac amyloidosis","volume":"36","author":"Yogeswaran","year":"2023","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.acvd.2025.12.010_bib0375","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jacc.2017.08.041","article-title":"Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study","volume":"70","author":"Prabhu","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0380","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jacc.2013.01.069","article-title":"A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure","volume":"61","author":"Jones","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0385","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2025.12.010_bib0390","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2022.04.045","article-title":"Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis","volume":"358","author":"Dale","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0395","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0400","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0405","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhsa.2022.09.005","article-title":"Results of implementation of amyloidosis screening for patients undergoing carpal tunnel release","volume":"49","author":"Gannon","year":"2024","journal-title":"J Hand Surg Am"},{"key":"10.1016\/j.acvd.2025.12.010_bib0410","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","article-title":"Monitoring clinical changes in patients with heart failure: a comparison of methods","volume":"150","author":"Spertus","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2025.12.010_bib0415","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/ehf2.12680","article-title":"Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure","volume":"7","author":"Kuster","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.12.010_bib0420","doi-asserted-by":"crossref","first-page":"597472","DOI":"10.3389\/fcvm.2020.597472","article-title":"Prognostic value of circulating sST2 for the prediction of mortality in patients with cardiac light-chain amyloidosis","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.acvd.2025.12.010_bib0425","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.24001","article-title":"Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.acvd.2025.12.010_bib0430","doi-asserted-by":"crossref","first-page":"e016614","DOI":"10.1161\/JAHA.120.016614","article-title":"Specific therapy for transthyretin cardiac amyloidosis: a systematic literature review and evidence-based recommendations","volume":"9","author":"Marques","year":"2020","journal-title":"J Am Heart Assoc"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213626000148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213626000148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:02:59Z","timestamp":1780660979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213626000148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1875213626000148"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2025.12.010","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tafamidis treatment in transthyretin cardiac amyloidosis: A retrospective cohort analysis of outcomes and associated factors","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}